Interlude Biopharma Co. has officially launched at the 21st International Celiac Disease Symposium (ICDS 2026) and announced plans to initiate a Phase 3 clinical trial of its investigational drug candidate, larazotide acetate, in the first quarter of 2027 in the United States.
The planned study will evaluate whether larazotide acetate can help prevent gluten-induced intestinal injury in people with celiac disease. The company is pursuing a prevention-focused approach designed to protect the intestinal barrier before gluten exposure triggers an inflammatory response.
Larazotide Acetate: Mechanism of Action
Larazotide acetate is an investigational oral peptide designed to regulate intestinal tight junctions, which control the permeability of the intestinal barrier.
It acts as a zonulin inhibitor, aiming to prevent gluten peptides from crossing the intestinal barrier and triggering the immune response associated with celiac disease.
Unlike approaches that focus on managing symptoms after inflammation occurs, larazotide acetate is designed to act at an earlier stage of the disease process.
The company is initially developing the drug as an adjunct to a strict gluten-free diet.
Phase 2b Clinical Evidence
The development programme is supported by previous clinical data, including a randomized, double-blind, placebo-controlled Phase 2b trial involving 342 patients with celiac disease who were following a gluten-free diet.
In that study, the 0.5 mg dose of larazotide acetate met its primary endpoint of reducing celiac disease symptoms.
The findings were published in the journal Gastroenterology and provided clinical support for further evaluation of the drug candidate.
Planned Phase 3 Trial: Study Design
Interlude's planned Phase 3 study is designed as a randomized, double-blind, placebo-controlled, multicenter superiority trial. The protocol has been approved, and the Investigational New Drug (IND) application is in effect.
Key trial details include:
| Parameter | Details |
|---|---|
| Trial registration | NCT07944625 |
| Planned enrolment | Approximately 414 participants |
| Population | Adolescents and adults aged 12–80 years |
| Disease status | Biopsy-confirmed, well-controlled celiac disease |
| Study sites | Up to 100 sites across the US |
| Treatment arms | Larazotide 0.25 mg, larazotide 0.5 mg or placebo |
| Administration | Three times daily for 14 weeks |
| Expected initiation | Q1 2027 |
Controlled Gluten Exposure
Following a run-in period, participants will receive a study bar containing 500 mg of gluten over a 12-week period.
The planned exposure schedule includes:
-
Every-other-day administration for the first four weeks.
-
Daily administration for the following eight weeks.
This controlled exposure is intended to represent the upper range of estimated inadvertent real-world gluten exposure.
Primary Endpoint
The primary endpoint will assess the proportion of responders who maintain intestinal mucosal architecture and symptom control, measured using the Celiac Disease Symptom Diary.
The trial is designed to evaluate both clinical symptoms and preservation of intestinal structure.
FDA Fast Track Designation
The US Food and Drug Administration (FDA) has granted Fast Track designation to larazotide acetate for the treatment of celiac disease.
According to the company, the FDA advised moving away from conventional interventional trial approaches towards a preventive study design that reflects the drug's proposed upstream mechanism of action.
The planned Phase 3 trial will therefore investigate whether protecting the intestinal barrier can help prevent gluten-induced injury rather than simply addressing symptoms after they develop.
Celiac Disease: Unmet Medical Need
Celiac disease is an autoimmune condition in which gluten ingestion triggers an immune response that damages the small intestine in genetically predisposed individuals.
Gluten is found in wheat, rye and barley. Even small amounts of accidental exposure can trigger symptoms and intestinal damage.
An estimated one in 100 people worldwide has celiac disease, although only approximately 30% are properly diagnosed, according to the company.
Currently, a lifelong strict gluten-free diet remains the only established management approach, and there are no FDA-approved pharmacological treatments specifically for celiac disease.
Development Outlook
Interlude Biopharma is preparing to advance larazotide acetate into Phase 3 clinical evaluation, with trial initiation expected in Q1 2027.
The study will examine whether the investigational therapy can preserve intestinal architecture and maintain symptom control during controlled gluten exposure.
If successful, the programme could support the development of an additional treatment option for people with celiac disease who remain vulnerable to accidental gluten exposure despite following a gluten-free diet. However, the drug's safety and efficacy will need to be established through the planned Phase 3 trial.
Clinical trial: NCT07944625 – ClinicalTrials.gov
Company: Interlude Biopharma Co., Miami, Florida, USA.